Patents by Inventor Donna M. Shattuck-Eidens

Donna M. Shattuck-Eidens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 17q-linked breast and ovarian cancer susceptibility gene
    Patent number: 6162897
    Abstract: The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast and ovarian cancer predisposing gene (BRCA1), some mutant alleles of which cause susceptibility to cancer, in particular breast and ovarian cancer. More specifically, the invention relates to germline mutations in the BRCA1 gene and their use in the diagnosis of predisposition to breast and ovarian cancer. The present invention further relates to somatic mutations in the BRCA1 gene in human breast and ovarian cancer and their use in the diagnosis and prognosis of human breast and ovarian cancer. Additionally, the invention relates to somatic mutations in the BRCA1 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA1 gene, including gene therapy, protein replacement therapy and protein mimetics.
    Type: Grant
    Filed: May 2, 1997
    Date of Patent: December 19, 2000
    Assignees: Myriad Genetics, Inc., University of Utah Research Foundation, The United States of America as represented by the Department of Health and Human Services
    Inventors: Mark H. Skolnick, David E. Goldgar, Yoshio Miki, Jeff Swenson, Alexander Kamb, Keith D. Harshman, Donna M. Shattuck-Eidens, Sean V. Tavtigian, Roger W. Wiseman, P. Andrew Futreal
  • 170-linked breast and ovarian cancer susceptibility gene
    Patent number: 5753441
    Abstract: The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast and ovarian cancer predisposing gene (BRCA1), some mutant alleles of which cause susceptibility to cancer, in particular breast and ovarian cancer. More specifically, the invention relates to germline mutations in the BRCA1 gene and their use in the diagnosis of predisposition to breast and ovarian cancer. The present invention further relates to somatic mutations in the BRCA1 gene in human breast and ovarian cancer and their use in the diagnosis and prognosis of human breast and ovarian cancer. Additionally, the invention relates to somatic mutations in the BRCA1 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA1 gene, including gene therapy, protein replacement therapy and protein mimetics.
    Type: Grant
    Filed: January 5, 1996
    Date of Patent: May 19, 1998
    Assignees: Myriad Genetics, Inc., University of Utah Research Foundation, The United States of America as represented by the Department of Health and Human Services
    Inventors: Mark H. Skolnick, David E. Goldgar, Yoshio Miki, Jeff Swenson, Alexander Kamb, Keith D. Harshman, Donna M. Shattuck-Eidens, Sean V. Tavtigian, Roger W. Wiseman, P. Andrew Futreal
  • 17Q-linked breast and ovarian cancer susceptibility gene
    Patent number: 5747282
    Abstract: The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast and ovarian cancer predisposing gene (BRCA1), some mutant alleles of which cause susceptibility to cancer, in particular breast and ovarian cancer. More specifically, the invention relates to germline mutations in the BRCA1 gene and their use in the diagnosis of predisposition to breast and ovarian cancer. The present invention further relates to somatic mutations in the BRCA1 gene in human breast and ovarian cancer and their use in the diagnosis and prognosis of human breast and ovarian cancer. Additionally, the invention relates to somatic mutations in the BRCA1 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA1 gene, including gene therapy, protein replacement therapy and protein mimetics.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: May 5, 1998
    Assignees: Myraid Genetics, Inc., University of Utah Research Foundation, The United States of America as represented by the Secretary of Health and Human Services
    Inventors: Mark H. Skolnick, David E. Goldgar, Yoshio Miki, Jeff Swenson, Alexander Kamb, Keith D. Harshman, Donna M. Shattuck-Eidens, Sean V. Tavtigian, Roger W. Wiseman, P. Andrew Futreal
  • 17q-linked breast and ovarian cancer susceptibility gene
    Patent number: 5710001
    Abstract: The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast and ovarian cancer predisposing gene (BRCA1), some mutant alleles of which cause susceptibility to cancer, in particular breast and ovarian cancer. More specifically, the invention relates to germline mutations in the BRCA1 gene and their use in the diagnosis of predisposition to breast and ovarian cancer. The present invention further relates to somatic mutations in the BRCA1 gene in human breast and ovarian cancer and their use in the diagnosis and prognosis of human breast and ovarian cancer. Additionally, the invention relates to somatic mutations in the BRCA1 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA1 gene, including gene therapy, protein replacement therapy and protein mimetics.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 20, 1998
    Assignees: Myriad Genetics, Inc., University of Utah Research Foundation, The United States of America as represented by the Secretary of Health and Human Services, Technology Transfer Office
    Inventors: Mark H. Skolnick, David E. Goldgar, Yoshio Miki, Jeff Swenson, Alexander Kamb, Keith D. Harshman, Donna M. Shattuck-Eidens, Sean V. Tavtigian, Roger W. Wiseman, P. Andrew Futreal
  • Linked breast and ovarian cancer susceptibility gene
    Patent number: 5709999
    Abstract: The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast and ovarian cancer predisposing gene (BRCA1), some mutant alleles of which cause susceptibility to cancer, in particular breast and ovarian cancer. More specifically, the invention relates to germline mutations in the BRCA1 gene and their use in the diagnosis of predisposition to breast and ovarian cancer. The present invention further relates to somatic mutations in the BRCA1 gene in human breast and ovarian cancer and their use in the diagnosis and prognosis of human breast and ovarian cancer. Additionally, the invention relates to somatic mutations in the BRCA1 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA1 gene, including gene therapy, protein replacement therapy and protein mimetics.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 20, 1998
    Assignees: Myriad Genetics Inc., Centre de Recherche du Chul, Cancer Institute
    Inventors: Donna M. Shattuck-Eidens, Jacques Simard, Francine Durocher, Mitsuuru Emi, Yusuke Nakamura
  • Linked breast and ovarian cancer susceptibility gene
    Patent number: 5693473
    Abstract: The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast and ovarian cancer predisposing gene (BRCA1), some mutant alleles of which cause susceptibility to cancer, in particular breast and ovarian cancer. More specifically, the invention relates to germline mutations in the BRCA1 gene and their use in the diagnosis of predisposition to breast and ovarian cancer. The present invention further relates to somatic mutations in the BRCA1 gene in human breast and ovarian cancer and their use in the diagnosis and prognosis of human breast and ovarian cancer. Additionally, the invention relates to somatic mutations in the BRCA1 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA1 gene, including gene therapy, protein replacement therapy and protein mimetics.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 2, 1997
    Assignees: Myriad Genetics, Inc., Centre de Recherche du Chul, Cancer Institute
    Inventors: Donna M. Shattuck-Eidens, Jacques Simard, Francine Durocher, Mitsuuru Emi, Yusuke Nakamura
  • Chrysanthemyl diphosphate synthase, corresponding genes and use in pyrethrin synthesis
    Patent number: 5443978
    Abstract: This invention provides a purified chrysanthemyl diphosphate synthase (CDS), a method for the purification of CDS from Chrysanthemum cinerariaefolium, and an amino acid sequence of the isolated CDS. Also provided is a cDNA encoding the CDS, a nucleotide sequence of the CDS gene, and a derived amino acid sequence of the encoded CDS protein. The CDS gene is useful in the enzymatic production of the natural stereospecific configuration of chrysanthemyl derivatives which are useful for the synthesis of pyrethrins, pyrethroids, derivatives thereof, as well as other classes of metabolites.
    Type: Grant
    Filed: June 25, 1993
    Date of Patent: August 22, 1995
    Assignee: Agridyne Technologies, Inc.
    Inventors: Suzanne R. Ellenberger, Galen D. Peiser, Russell N. Bell, Charles E. Hussey, Jr., Donna M. Shattuck-Eidens, Bradley D. Swedlund